ImportRefusal LogoImportRefusal

ELI LILLY CANADA INC

🚨 Critical Risk

FEI: 3016973244 • Toronto, ON • CANADA

FEI

FEI Number

3016973244

📍

Location

Toronto, ON

🇨🇦

Country

CANADA
🏢

Address

130 King St, Suit 900, Toronto, ON, Canada

Critical Risk

FDA Import Risk Assessment

80.0
LowModerateHighCritical

This firm has an extensive history of FDA import refusals with severe violations.

Statistics

39
Total Refusals
5
Unique Violations
12/22/2025
Latest Refusal
4/21/2021
Earliest Refusal

Score Breakdown

Violation Severity
85.1×40%
Refusal Volume
59.3×30%
Recency
98.9×20%
Frequency
83.4×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7537×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1183×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

20601×

AGRINSULIN

The article appears to be composed wholly or partly of insulin manufactured in the US and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for a medical emergency

3361×

INCONSPICU

Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

721×

NEW VET DR

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.

Refusal History

DateProductViolationsDivision
12/22/2025
61PCL74TIRZEPATIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/10/2025
61PCK74TIRZEPATIDE (ANTI-DIABETIC)
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/9/2025
61PCY74TIRZEPATIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/8/2025
58HCP09INSULIN GLARGINE
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/5/2025
61PCY74TIRZEPATIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/2/2025
61PCY74TIRZEPATIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/21/2025
58HCC06DULAGLUTIDE
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/14/2025
80FMFSYRINGE, PISTON
336INCONSPICU
Division of Southeast Imports (DSEI)
11/14/2025
58HCP09INSULIN GLARGINE
72NEW VET DR
Division of Southeast Imports (DSEI)
3/4/2025
58MDY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
58MDY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/27/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/21/2025
58MDY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/13/2025
58ODY06GUSELKUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/31/2025
62NCL99ANTI-PSORIATIC N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/31/2025
58MCK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/23/2025
66VCA99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/21/2025
61PCY58INSULIN LISPRO PROTAMINE (ANTI-DIABETIC)
118NOT LISTED
2060AGRINSULIN
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/16/2025
61PCK74TIRZEPATIDE (ANTI-DIABETIC)
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/7/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/7/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MCY11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2025
58MDK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/30/2024
61PCL74TIRZEPATIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/10/2024
58MCK11IXEKIZUMAB
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/8/2024
61PCY17INSULIN (INJ) (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/24/2024
61PCK19ISOPHANE INSULIN (SUSP) (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/12/2024
61PCY17INSULIN (INJ) (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/11/2024
61PDA17INSULIN (INJ) (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/5/2024
61PCP54LISPRO INSULIN (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/21/2021
66SDY51TADALAFIL
75UNAPPROVED
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is ELI LILLY CANADA INC's FDA import refusal history?

ELI LILLY CANADA INC (FEI: 3016973244) has 39 FDA import refusal record(s) in our database, spanning from 4/21/2021 to 12/22/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. ELI LILLY CANADA INC's FEI number is 3016973244.

What types of violations has ELI LILLY CANADA INC received?

ELI LILLY CANADA INC has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about ELI LILLY CANADA INC come from?

All FDA import refusal data for ELI LILLY CANADA INC is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.